Mirador Therapeutics closed a $250 million Series B and told Endpoints News it is weighing an initial public offering later this year. The financing backs Mirador’s precision-immunology pipeline targeting immune-mediated diseases and is positioned to fund late-stage development and manufacturing scale-up. Company executives framed the round as a step toward commercialization and potential public-market readiness.